BACKGROUND: Major depressive disorder is one of the most common and disabling mental health disorders and is associated with substantial costs in terms of direct health care utilization and workplace productivity. Cognitive dysfunction, which alone substantially increases health care costs, is commonly associated with major depressive disorder. However, the health care costs of cognitive dysfunction in the context of depressive disorder are unknown. Recovery from mood symptoms is not always associated with resolution of cognitive dysfunction. Thus, cognitive dysfunction may contribute to health care burden even with successful antidepressant therapy.
R E S E A R C H
• Major depressive disorder has an estimated lifetime prevalence of 10%-20% in the United States and imposes significant economic and societal consequences in terms of direct medical care costs, associated morbidity and mortality, and productivity costs.
• Cognitive dysfunction, which is commonly associated with major depressive disorder, may persist even after resolution of other symptoms of depression.
• By itself, a diagnosis of cognitive dysfunction is associated with up to triple the health care costs of persons without such a diagnosis. However, costs related to cognitive dysfunction in the context of depression have not been reported.
What is already known about this subject
• Using data from a large U.S. health plan, we analyzed health care utilization and costs for patients with a depressive disorder, with and without cognitive dysfunction, for 3 and 6 months following the initiation of antidepressant medication.
What this study adds
More patients in the cognitive normal cohort were white (P < 0.001) and employed full time (P = 0.029), had higher education attainment (P < 0.001), and had fewer comorbidities (P = 0.007) than those in the cognitive dysfunction cohort. Over the first 3 months, patients with cognitive dysfunction had higher adjusted all-cause costs ($3,309 vs. $2,157, P = 0.002) and higher adjusted depressive disorder-related costs ($718 vs. $406, P < 0.001) than patients without cognitive dysfunction. At 6 months, data from 4 patients were removed from the analysis because of exclusionary diagnoses. Over 6 months, patients with cognitive dysfunction had higher adjusted all-cause costs ($4,793) than patients without cognitive dysfunction ($3,683, P = 0.034). Over 6 months, depressive disorder-related costs did not significantly differ between patients with ($771) and without cognitive dysfunction ($594, P = 0.071). The main drivers of all-cause costs were office visits, outpatient hospital visits, and inpatient costs, and the main driver of depressive disorder-related costs was inpatient costs.
Patients
The study protocol received a waiver of authorization and ethics approval from the New England Institutional Review Board, and all patients completed informed consent and health information release forms. Patients had at least 1 pharmacy claim for an antidepressant between August 1 and September 30, 2012, and no claim for any antidepressant during the 6 months prior to the index date. Medical claims for recent depressive episodes were unavailable at the time of patient identification due to a 6-month lag required for complete medical claims; therefore, each patient confirmed a diagnosis of depression or MDD and the absence of any exclusionary neurological diagnoses possibly associated with cognitive impairment (see Appendices A-D, available in online article, for complete inclusion/exclusion criteria).
Demographics and Clinical Characteristics
Claims data from the baseline period were used to obtain age, gender, and geographic region; to identify comorbid conditions as defined in the Agency for Healthcare Research and Quality Clinical Classification Software; and to calculate the QuanCharlson Comorbidity Index score based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes (a measure of comorbidity burden). 13, 14 Eligible patients interviewed by telephone provided race and ethnicity, employment status, occupation, and highest education level achieved. Patient-reported outcome assessments measuring depression severity, disability, self-reported cognitive functioning, and health-related quality of life were also administered, and these results are reported separately. 15 M ajor depressive disorder (MDD) is one of the most common and disabling mental health disorders, with a lifetime prevalence estimated at 10%-20% in the United States and with higher rates for women than men. [1] [2] [3] Depression has significant economic and societal consequences. In 2000, the estimated costs of depression were $83.1 billion, including $26.1 billion in direct medical costs and $51.5 billion in workplace productivity costs. 4 Per patient annual direct medical costs of depression up to $2,500 have been reported. 5 As a major health problem associated with gradual and often incomplete recovery, MDD imposes significant limitations on functioning and well-being, raises the risk of mortality due to medical illness, and increases utilization of health services and associated costs to society. 6 Cognitive dysfunction is commonly associated with MDD and is characterized by "difficulty thinking, concentrating, or making decisions," which is part of the MDD diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. 7 Resolution of depression is not always associated with recovery from cognitive dysfunction, and there is increasing evidence of persistent cognitive dysfunction even after resolution of depressive symptoms. [8] [9] [10] Thus, cognitive dysfunction may contribute to health care burden even after successful treatment of other symptoms of MDD.
Cognitive dysfunction by itself is associated with higher health care costs. In fact, people diagnosed with dementia, an extreme form of cognitive dysfunction, have experienced triple the health care costs of persons with no such diagnosis.
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The costs related to cognitive dysfunction in the context of depression have not been reported. The objectives of this study were to compare health care utilization and costs from a payer perspective for patients with a depressive disorder, with and without cognitive dysfunction, for 3 months and 6 months after the start of antidepressant medication. These results will be of importance to health care providers and payers involved with the treatment of patients with a depressive disorder experiencing cognitive dysfunction.
• Patients with cognitive dysfunction had significantly more allcause outpatient hospital visits during the first 3 months after initiating antidepressant medication. At 6 months, patients with cognitive dysfunction had significantly more all-cause emergency room visits and depressive disorder-related outpatient visits.
• Relative to patients without cognitive dysfunction, patients with cognitive dysfunction had significantly higher all-cause and depressive disorder-related health care costs 3 months following initiation of an antidepressant and higher all-cause costs 6 months following initiation of an antidepressant. [16] [17] [18] These tests were chosen because they represent the domains found to be most impaired in acute depression and have been shown to be sensitive to depression-related cognitive dysfunction. [19] [20] [21] Performance on each test was compared with published ageand gender-stratified normative data and then used to classify each patient's cognition as either normal or dysfunctional. [16] [17] [18] Patients were classified as having "cognitive dysfunction" if they met at least 1 of 2 criteria: (1) two or more test scores 1.5 standard deviations (SD) or more below the normative mean, or (2) three or more test scores 1.0 SD or more below the normative mean. 22 Patients not meeting either of these criteria were classified as "cognitive normal." See Figure 1 for cohort assignment.
Assessment of Cognitive Function

Health Care Utilization and Costs
Health care utilization and costs from a payer perspective were calculated from pharmacy and medical claims 6 months prior (baseline) to antidepressant initiation, 3 months after initiation of antidepressant medication (3-month follow-up), and 6 months (including the 3-month follow-up) after initiation of antidepressant medication (6-month follow-up). Health care costs represent the sum of health plan and patient-paid amounts and were classified as follows: office visits, outpatient hospital visits, emergency room, inpatient, other medical, pharmacy, and total costs (combining all of these categories). An example of "other medical" costs would be independent laboratory and diagnostic costs. "All-cause" costs included the cost of all health care utilization consumed during the study period, regardless of the diagnosis, and "depressive disorderrelated" costs included medical claims having a primary or nonprimary diagnosis code for, or relating to, depressive disorder (ICD-9-CM codes 296.82 [atypical depressive disorder], 296.2x [major depressive disorder, single episode], 296.3x [major depressive disorder, recurrent episode], 311 [depressive disorder, not elsewhere classified]) and associated pharmacy claims (see Appendices B and E, available in online article).
Statistical Analyses
Chi-square and t-tests were used to compare demographic characteristics and health care utilization between the cognitive dysfunction and cognitive normal cohorts for categorical and continuous variables, respectively. Two-sided t-tests were used to compare health care costs between the 2 cohorts. We used a generalized linear model (GLM) with gamma distribution and log link to assess the relationship between cognitive function and total all-cause costs, controlling for potential confounders of performance on neuropsychological tests (level of education, race, gender, age, level of employment, Quan-Charlson comorbidity score, and mental health-related comorbidities). Because health care costs are often skewed, estimated cost measures were modeled using Manning and Mullahy's formulation. 23 This method avoids potential difficulties introduced by transformation and retransformation of the dependent variable. 24 Coefficients from a GLM are estimated cost ratios.
Adjusted costs for all-cause health care utilization were estimated from the gamma models for 3-and 6-month follow-up periods. The same approach was used to assess the relationship between cognitive function and depressive disorder-related costs, controlling for the same potential confounders.
A logistic regression analysis in which presence of nonzero baseline costs (measured as a binomial) as the dependent variable was performed with a single independent (predictor) variable as presence of cognitive dysfunction (measured as a binomial). Logistic regression assesses the relationship between a binomial (or categorical) dependent variable and a set of independent variables. This model was used because the binomial outcome variable violates assumptions of ordinary least squares regression. A GLM with log link and gamma distribution assessed the relationship between cognitive dysfunction (as a single, binomial predictor variable) and nonzero baseline costs.
■■ Results
Study Sample
Of the 13,537 patients who were mailed an invitation to participate in the study, 824 (6%) were eligible and agreed to participate ( Figure 1 ). Of this number, 563 patients completed the informed consent process, completed a telephone interview, maintained eligibility, and were included in the calculation of 3-month health care utilization and costs. Four patients were removed from the calculation of 6-month costs because they had an exclusionary diagnosis of bipolar disorder during the 6-month follow-up period, leaving 559 patients in the 6-month analysis.
Demographics
Of the 563 patients in the 3-month follow-up analysis, 255 (45%) met the criteria for cognitive dysfunction. The mean patient age was 41.3 (SD = 12.5) years, and 80% were female. Most patients were white and employed. More patients in the cognitive normal cohort were white and employed full time, had higher education, and had fewer comorbidities compared with patients in the cognitive dysfunction cohort. Demographic details are shown in Table 1 .
Costs at Baseline
In the 6 months prior to antidepressant initiation (baseline), the unadjusted all-cause costs were $6,431 for the cognitive dysfunction cohort compared with $3,953 for the cognitive normal cohort 
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(P = 0.067; Table 2 ). The main cost drivers for all-cause costs were office visits, outpatient hospital visits, and inpatient costs. The mean 6-month baseline unadjusted depressive disorderrelated total costs were $782 for the cognitive dysfunction cohort compared with $108 for the cognitive normal cohort (P = 0.133).
The main cost driver for the depressive disorder-related costs in the cognitive dysfunction cohort was inpatient costs of $702 for 4 patients with hospitalizations. There were no inpatient costs in the cognitive normal cohort. The results from the multiple logistic regression models comparing the proportion of patients with costs to patients without costs found no significant difference between the 2 cohorts for unadjusted all-cause (P = 0.503) or unadjusted depressive disorder-related costs (P = 0.557).
The gamma models with a log link that compared costs for all patients, including patients with no costs, found a significant difference between the 2 cohorts for unadjusted allcause (P < 0.001) and unadjusted depressive disorder-related costs (P < 0.001). When inpatient costs were removed from the gamma model, the difference in unadjusted depressive disorder-related costs between the cohorts was no longer significant. 
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After Initiating Antidepressant Medication for Depressive Disorders which accounted for one-quarter of total costs. The difference between the 2 cohorts was significantly higher (P = 0.012 and 0.011) for outpatient hospital visits in the cognitive dysfunction cohort for the 3-and 6-month periods and emergency room visits (P = 0.047) for the 6-month period. Median costs were similar across the 2 cohorts for the 3-month and 6-month total costs and cost components (i.e., office, outpatient hospital, emergency room, inpatient, other medical, and pharmacy). The adjusted gamma model yielded significant differences in mean all-cause costs ( Table 2) . At 3 months, patients with cognitive dysfunction had higher adjusted all-cause costs compared with patients in the cognitive normal cohort ($3,309 vs. $2,157, P = 0.002). Patients with cognitive dysfunction also had higher 6-month adjusted all-cause costs than those without cognitive dysfunction ($4,793 vs. $3,683, P = 0.034). Gamma models yielded cost ratios (see Appendix F, available in online article) for all-cause costs at 1.53 times higher (95% confidence interval [CI] = 1.17-2.02, P = 0.002) for patients with cognitive dysfunction than for patients without cognitive dysfunction at 3 months. In addition, baseline Quan-Charlson score > 0 and full-time employment were significantly and positively associated with all-cause costs during the 3-month follow-up period. The cost ratio at 6 months for all-cause costs was 1.30 times higher (95% CI = 1.02-1.66, P = 0.034) for the cognitive dysfunction cohort than the cognitive normal cohort. Baseline Quan-Charlson score > 0 was significantly and positively associated with all-cause costs during the 6-month follow-up period. Table 3 provides the number of patients with at least 1 occurrence of health care utilization as well as the mean number per patient, including those patients with no use of health care utilization. Significantly more patients with cognitive dysfunction than without had all-cause outpatient hospital visits over the first 3 months after antidepressant initiation (32.6% vs. 24.7%, P = 0.039; Table 3 ). Over 6 months, 46.8% of patients with cognitive dysfunction had all-cause outpatient hospital visits compared with 40.1% of patients without cognitive dysfunction; however, the difference between cohorts was no longer statistically significant (P = 0.108). Over 6 months, more patients with cognitive dysfunction had an all-cause emergency room visit compared with patients without cognitive dysfunction (29.0% vs. 19.5%, P = 0.009). Over that span, significantly more patients with cognitive dysfunction than without had an outpatient visit for depressive disorder (8.3% vs. 4.2%, P = 0.044).
Follow-up Health Care Utilization
Follow-up All-Cause Costs
At 3 months, the difference in unadjusted all-cause total costs was not statistically significant (P = 0.113; Tables 2 and 4) . By 6 months, however, the unadjusted all-cause total costs were significantly higher ($6,707) for patients with cognitive dysfunction compared with those without cognitive dysfunction ($3,938, P = 0.040; Tables 2 and 4). For both follow-up periods, the largest cost drivers were office and outpatient visits, which accounted for half of total costs, followed by inpatient costs, 
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In the adjusted gamma model, patients with cognitive dysfunction had significantly higher 3-month depressive disorderrelated total costs ($718) compared with patients without cognitive dysfunction ($406, P < 0.001; Table 2 ). The cost ratio (see Appendix F, available in online article) indicated 1.77 times (95% CI = 1.30-2.41, P < 0.001) higher depressive disorder-related costs for patients with cognitive dysfunction than those without.
In addition, baseline Quan-Charlson score > 0 and fulltime employment were significantly and positively associated with all-cause costs during the 3-month follow-up period. At 6 months, the ratio was 1.30 times (95% CI = 0.98-1.72, P = 0.071) higher costs for patients with cognitive dysfunction. Baseline Quan-Charlson score > 0 and full-time employment
Follow-up Depressive Disorder-Related Costs
The difference in unadjusted depressive disorder-related total costs were not statistically significant by 3 months (P = 0.536; Tables 2 and 4) or by 6 months (P = 0.387). The largest cost drivers were inpatient care, which accounted for approximately two-thirds of the total depressive disorder-related costs, followed by outpatient hospital visits, office visits, and pharmacy costs, with each accounting for less than onequarter of the costs. The outpatient hospital costs at 6-months post-index were significantly higher (P = 0.030) among the cognitive dysfunction cohort compared with the cognitive normal cohort. The median costs were similar across the 2 cohorts for the 3-month and 6-month total costs and cost components. 
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were significantly and positively associated with all-cause costs during the 6-month follow-up period.
■■ Discussion
In this study, we classified patients with depressive disorder from an ambulatory care setting into cognitive dysfunction or cognitive normal cohorts, based on standard assessments of cognitive function. We compared all-cause and depressive disorder-related costs across the 2 cohorts to determine if costs for patients with cognitive dysfunction were higher than costs for patients without cognitive dysfunction. In addition, the types of health care services that accounted for the costs for each cohort were identified. For all patients, regardless of cognitive dysfunction, the main drivers of all-cause costs prior to and following antidepressant initiation were office visits, outpatient hospital visits, and inpatient costs. The main driver of depressive disorder-related costs was inpatient costs. These results for depressive disorder-related costs are consistent with results from a systematic review of cost-of-illness studies in depression that found inpatient costs to be cost drivers, followed by outpatient costs and pharmacy costs. 5 The cognitive normal cohort had more patients who were white and employed full time; this cohort also had higher education and fewer comorbidities. Thus, the associations between cognitive dysfunction and total follow-up costs were tested with adjustment for potential confounders. After 
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adjustment, compared with patients without cognitive dysfunction, patients with cognitive dysfunction had significantly higher all-cause and depressive disorder-related health care costs over 3 months and higher all-cause costs over 6 months. Over 6 months, the difference in unadjusted all-cause costs between patients with cognitive dysfunction and those without was $2,769 ($6,707-$3,938); controlling for potential confounders, the difference was $1,110 ($4,793-$3,683). These differences in all-cause costs may be attributed to the greater need for follow-up services in patients with cognitive dysfunction, that is, to the additional cost of treating cognitive dysfunction following antidepressant treatment. Likewise, the difference over 6 months in unadjusted depressive disorder-related costs was $557 ($1,316-$759); controlling for confounders, it was $177 ($771-$594). These differences in costs could also be attributable to the additional depressive disorder-related treatment of cognitive dysfunction (greater need for follow-up services in patients with cognitive dysfunction).
We are not aware of any published work measuring the additional costs of treating cognitive dysfunction in patients with depressive disorders against which to compare our results. However, 2 studies did measure the additional costs of other concomitant conditions in patients with MDD. One study, a U.S. claims-based study, found increased costs in patients with MDD who were taking insomnia medication. 25 Patients taking insomnia medication had higher annual adjusted all-cause costs ($3,918 more) and adjusted MDD-related costs ($537 more), compared with MDD patients not taking insomnia medication. Another U.S. claims-based study found that patients with MDD and anxiety had higher annual costs ($10,031) than patients with MDD only ($6,681), a difference of $3,350. 26 Our unadjusted all-cause cost of treating patients with cognitive dysfunction over 6 months was $2,769, and our adjusted cost was $1,110; annualized, these are $5,538 and $2,220. These numbers are comparable with the all-cause costs of insomnia at $3,918 and anxiety at $3,350. Our unadjusted depressive disorder-related cost of treating patients with cognitive dysfunction over 6 months was $557, and our adjusted cost was $177, which when annualized are $1,114 and $354-comparable to the MDD-related cost of insomnia at $537.
The annual cost to treat patients with MDD only ($6,681) in the study of MDD with anxiety, 26 and the unadjusted cost to treat MDD patients without insomnia ($7,015), 25 can be compared with the cost of our depressive-disorder patients without cognitive dysfunction to compare the costs of treating depression. Our annualized (unadjusted all-cause $7,876 [$3,938 × 2] and adjusted all-cause $7,366 [$3,683 × 2]) costs were similar. The mean unadjusted annual MDD-related cost in patients without insomnia was $824, 25 compared with the depressive disorder-related costs of our patients without cognitive dysfunction, when our costs are annualized (unadjusted depressive disorder-related $1,518 [$759 × 2] and adjusted depressive disorder-related $1,188 [$594 × 2]). The systematic review of cost-of-illness studies of depression found an average annual direct medical cost of $1,000 to $2,500.
Another study found that patients with diabetes and a dementia diagnosis in 2005 had total average Medicare payments in 2006 of $20,655 compared with $12,979 in patients with diabetes and no dementia diagnosis, for a difference of $7,676. 11 This cost of dementia is higher than our annualized unadjusted all-cause cost of $5,538 and our annualized adjusted all-cause cost of $2,220 for treating cognitive dysfunction. Our lower costs for cognitive dysfunction is not surprising because patients with dementia have more severe cognitive dysfunction, and there are other additional confounders, such as comorbidities, age, and medication. Although we did not measure the long-term consequences of not treating cognitive dysfunction, our data support the consideration that cognitive dysfunction is an important symptom with cost implications similar to other chronic illnesses.
In fact, a recent meta-analysis identified cognitive deficits in patients with first-episode MDD and suggested that cognitive deficits appear to be a feasible early marker and target for early intervention in MDD. 19 Patients in our study with cognitive dysfunction had higher all-cause and depressive disorder-related costs compared with patients with no cognitive dysfunction, and this difference persisted for all-cause costs through 6 months. Therefore, identifying and treating cognitive dysfunction and depressive disorder may save downstream costs to the health care system.
Limitations
We acknowledge several limitations of this study. The original study was designed to compare clinical outcomes between groups, and the secondary objective was to compare costs. 15 Direct medical costs were included in the results; however, indirect costs can be substantial and were not included. 5 The total follow-up costs were adjusted for potential confounders; however, the component follow-up costs (and baseline costs) were not adjusted because several components of total followup costs had zero costs, which is not conducive to a modelbased adjustment. The severity of baseline depression could not be determined and therefore was also not included as a potential confounder. This sample was drawn from a much larger sample population, and a selection bias could exist. However, this lack of representativeness does not invalidate the results of the study, since the mechanisms underlying higher health care costs for depressed patients with cognitive dysfunction can be considered as independent of the representativeness of the sample, as with most relations identified in epidemiological studies. 27 The sample includes only patients with commercial insurance, who were aged 18-65 years and 80% female, and most of whom were employed, so it may not be representative of the general population. The nature of claims data collection limited the speed with which identification, recruitment, and participation in the survey followed the index date
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After Initiating Antidepressant Medication for Depressive Disorders (antidepressant initiation). Patients with cognitive dysfunction at the index date may have benefitted from treatment and been classified as cognitive normal by the time they received their telephone interviews. This may bias the results to having a higher cost in the cognitive normal group because of earlier cognitive dysfunction. The remaining patients with cognitive dysfunction may have had a higher severity of cognitive dysfunction and raised the cost in the cognitive dysfunction group. Another limitation was having cognitive dysfunction measured at 1 time point only. By 6 months, the difference between groups in depressive disorder-related costs was no longer significant after adjusting for confounders, and it could be that patients may not have remained in the original classification of cognitive normal or cognitive dysfunction. Our standard assessments were provided over the telephone. Although the interviewers were trained specifically for this study by neuropsychologists, they were not neuropsychologists themselves. In addition, our method of collectively taking results of 4 cognitive assessment measures to classify patients by cognitive function has not been validated, although each of these cognitive instruments has been validated individually.
■■ Conclusions
In this study of patients with depressive disorder, all-cause and depressive disorder-related adjusted health care costs over 3 months were significantly higher in patients with cognitive dysfunction compared with those without cognitive dysfunction. By 6 months, although the difference in depressive disorder-related costs was no longer significant after adjusting for confounders, the adjusted all-cause costs remained significantly higher for patients with cognitive dysfunction. These data support the idea that cognitive dysfunction is associated with higher health care costs in depressed individuals and may be a useful target symptom for future treatment advances.
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Inclusion Criteria
At least 1 pharmacy claim for an antidepressant listed in Appendix B during the identification period based on the most currently available pharmacy claims data (approximately August and September 2012). Identification of the antidepressant will occur at the end of the month when the claims database has been updated. The identification period will include the current month (up to the date the database has been updated) and the prior month.
The index date will be defined as the date of the first antidepressant pharmacy claim for the antidepressant. The antidepressant a patient receives on the index date will be defined as the index antidepressant.
No pharmacy claim for any antidepressant medication 6 months prior to initiation of index antidepressant; the 6-month period before the index date will be defined as the baseline period. Aged 18 to 65 years as of the year of the index date. Self-reported major depressive disorder diagnosis in the invitation reply and patient survey. Self-reported confirmation of no diagnoses of schizophrenia, bipolar disorder, epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease in the invitation reply and patient survey. Continuous enrollment in a large commercial U.S. health plan affiliated with OptumInsight during the baseline period.
Mental health coverage with OptumHealth Behavioral Solutions (OHBS).
Willingness to sign and return the informed consent and health information release forms.
Willingness and ability to participate in a telephone interview conducted in English.
Exclusion Criteria
Expiration of health plan enrollment 6 months or less from the index date. Any claim with a primary or secondary diagnosis code for schizophrenia, bipolar disorder, Alzheimer's disease, epilepsy disorder, Huntington's disease, Parkinson's disease, and multiple sclerosis during the 1 year prior to initiation of index antidepressant. Any prescription for 1 of the following conditions: schizophrenia, bipolar disorder, Alzheimer's disease, epilepsy disorder, Huntington's disease, Parkinson's disease, and multiple sclerosis during the baseline period. 
APPENDIX A Inclusion and Exclusion Criteria
APPENDIX F
Analysis of All-Cause and Depressive Disorder-Related Cost Ratios by Follow-up Period
